Extremity Medical launched BioFuse, a next-gen viable cell bone graft for use in the foot, ankle, wrist and hand. The product complements Extremity Medical’s planned 2017 launches, such as the AXIS Charcot Fixation, KinematX Total Wrist Arthroplasty, MTP fusion and Jones fracture systems.
BioFuse comprises cells, biologic stimulants and a scaffold to support robust bone formation, with proprietary processing that allows rapid harvesting and reduced exposure to stressors that damage cells.
In vitro testing indicates that BioFuse provides higher levels of osteoinductive biologic stimulants and increased osteoconductivity vs. traditionally-processed live bone cell grafts.
Sources: Extremity Medical, LLC; ORTHOWORLD Inc.
Extremity Medical launched BioFuse, a next-gen viable cell bone graft for use in the foot, ankle, wrist and hand. The product complements Extremity Medical's planned 2017 launches, such as the AXIS Charcot Fixation, KinematX Total Wrist Arthroplasty, MTP fusion and Jones fracture systems.
BioFuse comprises cells, biologic stimulants and a...
Extremity Medical launched BioFuse, a next-gen viable cell bone graft for use in the foot, ankle, wrist and hand. The product complements Extremity Medical’s planned 2017 launches, such as the AXIS Charcot Fixation, KinematX Total Wrist Arthroplasty, MTP fusion and Jones fracture systems.
BioFuse comprises cells, biologic stimulants and a scaffold to support robust bone formation, with proprietary processing that allows rapid harvesting and reduced exposure to stressors that damage cells.
In vitro testing indicates that BioFuse provides higher levels of osteoinductive biologic stimulants and increased osteoconductivity vs. traditionally-processed live bone cell grafts.
Sources: Extremity Medical, LLC; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
